Retinyl hexanoate

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: Retinyl hexanoate
• 英文别名: [(2E,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraenyl] hexanoate
• 化学式: C₂₆H₄₀O₂
• 分子量: 384.6
• InChiKey: JOHZSPKDCASWAX-BAJOQGENSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  8.2
• 重原子数：
  28
• 可旋转键数：
  11
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.58
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  维生素A 、 己酸酐 生成 Retinyl hexanoate
  参考文献：
  名称：

  FURR, HAROLD C.;ZENG, SIHUI;CLIFFORD, ANDREW J.;OLSON, JAMES A., J. CHROMATOGR. BIOMED. APPL., 527,(1990) N, C. 406-413

  摘要：

  DOI：

文献信息

• Chroman derivatives as lipoxygenase inhibitors
  申请人：Zhang Wei

  公开号：US20060193797A1

  公开（公告）日：2006-08-31

  The present invention is concerned with certain novel derivatives of Formula I: wherein X and R 1 to R 10 are as described in the specification, and where either R 5 is OH, —NR d OR a or —NR d —NR b R c , or R 7 is —NR d OR a or —NR d —NR b R c , or C═R 7 R 8 is C═NOR a or C═N—NR b R c , which may be useful in the manufacture of pharmaceutical compositions for treating disorders mediated by lipoxygenases. They may also be useful in the manufacture of skin care and/or pharmaceutical compositions for the treatment of lipoxygenase mediated disorders.

  本发明涉及Formula I的某些新颖衍生物：其中X和R1至R10如规范中所述，其中R5为OH，—NRdORa或—NRd—NRbRc之一，或R7为—NRdORa或—NRd—NRbRc之一，或C═R7R8为C═NORa或C═N—NRbRc，这些可能在制造用于治疗通过脂氧合酶介导的疾病的药物组合物中有用。它们还可能在制造用于治疗脂氧合酶介导疾病的皮肤护理和/或药用组合物中有用。
• Management of ophthalmologic disorders, including macular degeneration
  申请人：Rando R. Robert

  公开号：US20060069078A1

  公开（公告）日：2006-03-30

  A drug may be used in the preparation of a medicament for the treatment or prevention of an ophthalmologic disorder, wherein the drug inihibits, antagonizes, or short-circuits the visual cycle at a step of the visual cycle that occurs outside a disc of a rod photoreceptor cell.

  一种药物可以用于制备治疗或预防眼科疾病的药物，其中该药物抑制、拮抗或短路视觉循环，该视觉循环发生在杆状感光细胞的盘外步骤。
• Management of Ophthalmologic Disorders, Including Macular Degeneration
  申请人：Rando Robert R.

  公开号：US20080176952A1

  公开（公告）日：2008-07-24

  A drug may be used in the preparation of a medicament for the treatment or prevention of an ophthalmologic disorder, wherein the drug inhibits, antagonizes, or short circuits the visual cycle at a step of the visual cycle that occurs outside a disc of a rod photoreceptor cell.

  一种药物可用于制备用于治疗或预防眼科疾病的药物，其中该药物抑制、拮抗或短路视觉周期，在视网膜杆细胞盘外发生的视觉周期步骤中。
• Skin care compositions containing dimethyl imidazolidinone and retinol or retinyl ester
  申请人：UNILEVER PLC

  公开号：EP0745375A1

  公开（公告）日：1996-12-04

  Dimethyl imidazolidinone in combination with either retinol or retinyl ester resulted in a synergistic enhancement in keratinocyte proliferation and synergistic inhibition of keratinocyte differentiation. The effects of the retinol or retinyl esters in combination with dimethyl imidazolidinone were analogous to treatment with retinoic acid.

  二甲基咪唑烷酮与视黄醇或视黄醇酯结合使用，可协同促进角质形成细胞的增殖，并协同抑制角质形成细胞的分化。视黄醇或视黄醇酯与二甲基咪唑烷酮结合使用的效果与视黄酸治疗类似。
• Skin care compositions containing a retinoid
  申请人：UNILEVER PLC

  公开号：EP0803247A2

  公开（公告）日：1997-10-29

  Melinamide in combination with retinol or retinyl ester resulted in a synergistic enhancement in keratinocyte proliferation. The effects of the retinol or retinyl esters in combination with melinamide were analogous to treatment with retinoic acid.

  美利那酰胺与视黄醇或视黄酯结合使用可协同增强角质细胞的增殖。视黄醇或视黄醇酯与美利那酰胺结合使用的效果与视黄酸类似。